Powering the genetic medicine revolution
Our novel, synthetic DNA vector, doggybone DNA or dbDNA™, and its enzymatic production, enable us to make DNA at the speed, scale and purity necessary to support the rapid growth of genetic medicines.
DNA made using enzymes
We are disrupting the decades-old technology of DNA production, moving away from restrictive biological approaches to instead use a synthetic DNA vector.Our platform technology
Enzymatic manufacturing enables multi-gram GMP DNA production in weeks rather than months
Manufactured using benchtop equipment with a significantly smaller footprint than fermentation-based production
doggybone DNA technology is highly portable and amenable to technology transfer
doggybone DNA can encode long, complex, unstable sequences, eliminates bacterial sequences, and has a strong expression profile
Addressing a broad market
Our versatile doggybone DNA (dbDNA) technology is being applied across the genetic medicine industry.
What can we do for you?
We offer a range of services to support development and commercialisation of the next generation of DNA products.
- Catalogue products
- Molecular biology
- Custom research grade
- Toxicology materials
- GMP dbDNA™ (critical starting materials)
- GMP dbDNA™ (drug substance)
- Commercial supply / on-site supply
- Analytical development
- Scale up development
- Regulatory support
Headquartered in Hampton
Take a tour of our stunning buildings and state-of-the-art DNA manufacturing facilities.View our facilities
Webinar – doggybone DNA: A Rapid Enzymatic GMP Starting Material for mRNA ProductionRead Article
MegaBulb DNA (mbDNA) – a novel circular ssDNA CRISPR template for gene editingRead Article
Clarivate Podcast – Lighting the touch paper for next generation nucleic acid therapiesRead Article
Webinar – Supporting the Clinical Adoption of Enzymatic DNA in Advanced Therapy ManufacturingRead Article
21 November 2023
Touchlight’s enzymatic doggybone DNA used in the manufacture of Versameb’s VMB-100 for first-in-human clinical study
Based on prior manufacturing agreement that encompasses usage of Touchlight’s doggybone DNA (dbDNA™) to manufacture clinical supply of VMB-100 for Phase 2a trial to treat stress urinary incontinence (SUI). Hampton,...
01 September 2023
Touchlight appoints SVP, Global Head of Sales
Touchlight, a biotechnology CDMO enabling the development of genetic medicines with its enzymatic doggybone DNA technology, is delighted to announce the appointment of Dr Verna McErlane as its SVP, Global...
We'd like to hear from you
For more information on how our doggybone DNA technology could help advance your project, please contact us.Get in touch